Cancer Research Technology (CRT) has signed a deal to provide Valirx with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.
The compound, now called VAL 201, has been shown in preclinical tests in mice to stop growth of tumours that have been unresponsive to hormone treatments.
VAL 201 blocks genes that can cause prostate cancer to develop, The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.
Under the terms of the deal, Valirx has exclusive rights to use the compound to treat, prevent and diagnose cancer and other diseases.
Cancer Research Technology - Cancer Research UK's development and commercialisation arm - will receive milestone payments throughout the development and commercialisation of the compound and royalty payments for potential licensed treatments.
Under the terms of the licence with Cancer Research Technology, Valirx will be responsible for performing the pre-clinical regulatory development of VAL 201 to prepare the compound for early clinical trials in patients.
Valirx will manage the commercialisation of potential treatments after clinical trials.
